Anika Therapeutics, Inc.
NASDAQ:ANIKMedical - Devices
-$0.06 today
- Market cap
- $182.44M
- Beta
- 0.23
- P/E (TTM)
- -17.3
- EPS (TTM)
- -$0.82
Volume 0.12M
Average 0.11M
ANIK Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Anika Therapeutics, Inc.NASDAQ: ANIK
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items growth accelerates
Q1 FY2026 other non-cash items of $1.24M rose 130.2% year over year, ahead of the -84.8% change in trailing-twelve-month other non-cash items. Sequentially, it fell 28.1% from the prior quarter. Over 3 fiscal years it compounded at -2.1% a year.
Context
- Other non-cash items amounted to 6.3% of revenue in FY2025, down 38.2 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +130.2% holds above the trailing-twelve-month pace of -84.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 7.09M USD
- Year-over-year change
- -86.7%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.09M | -86.7% |
| FY2024 | 2024-12-31 | 53.37M | -23.6% |
| FY2023 | 2023-12-31 | 69.87M | +824.6% |
| FY2022 | 2022-12-31 | 7.56M | +262.3% |
| FY2021 | 2021-12-31 | (4.66M) | — |
Other Non-Cash Items vs competitors
How ANIK compares with its peers on the latest reported figures
- ANIK's LTM Mar 2026 other non-cash items of $7.79M is the 5th largest of the 9 companies compared; the peer median is $3.48M.
- Its year-over-year change of -84.8% is the 7th highest of 9, against a peer median of +221.5%.
- Other non-cash items amounts to 6.7% of revenue for ANIK, versus a peer median of 31.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.91B | +161769.7% | +139.5% | 465745.8% | |
| LTM Mar 2026 | $33.28M | +1480.2% | — | 31.1% | |
| LTM Mar 2026 | $26.81M | -156.2% | +158.7% | 46.5% | |
| LTM Mar 2026 | $9.6M | +22.7% | -40.2% | 29.7% | |
| LTM Mar 2026 | $7.79M | -84.8% | -2.1% | 6.7% | |
| LTM Mar 2026 | $4.13M | +324.3% | +55.0% | 12.0% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $3.12M | -337.9% | — | 168.7% |
| LTM Mar 2026 | $2.83M | +118.8% | +48.1% | 5.1% | |
| LTM Apr 2026 | $855K | +383.1% | -44.4% | — | |
| Peer median (excluding ANIK) | $3.48M | +221.5% | +51.5% | 31.1% | |
Competitors are the stored peer set for ANIK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 4.13M | (14.86M) | (82.67M) | (56.39M) | (10.88M) |
| Depreciation & Amortization | 14.32M | 14.49M | 14.22M | 8.12M | 5.73M |
| Deferred Income Tax | (1.77M) | (5.27M) | (6.33M) | 260K | (7K) |
| Stock-Based Compensation | 11.09M | 14.32M | 15.24M | 13.13M | 10.08M |
| Change in Working Capital | (14.72M) | (11.82M) | (12.12M) | (13.09M) | (823K) |
| Accounts Receivables | (6.22M) | (5.63M) | (1.31M) | 3.37M | 408K |
| Inventory | (6.62M) | (6.87M) | (11.4M) | (9.42M) | 30K |
| Accounts Payables | (1.1M) | 1.97M | (11K) | (2.51M) | 42K |
| Other Working Capital | (783K) | (1.28M) | 589K | (4.53M) | (1.3M) |
| Other Non-Cash Items | (4.66M) | 7.56M | 69.87M | 53.37M | 7.09M |
| Operating Cash Flow | 8.4M | 4.41M | (1.79M) | 5.4M | 11.19M |
| Capital Expenditures | (5.14M) | (7.49M) | (5.43M) | (7.73M) | (6.83M) |
| Acquisitions (Net) | (476K) | 0 | 0 | 0 | 8.99M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 2.5M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (600K) | (2.57M) |
| Investing Cash Flow | (3.12M) | (7.49M) | (5.43M) | (8.33M) | (401K) |
| Debt Repayment | (201K) | (284K) | 0 | 0 | 0 |
| Common Stock Issued | 1.13M | 681K | 0 | 0 | 500K |
| Common Stock Repurchased | 0 | 0 | (5M) | (10.91M) | (9.49M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.71M) | (5.25M) | (1.32M) | (1.82M) | (1.57M) |
| Financing Cash Flow | (6.78M) | (4.85M) | (6.32M) | (12.73M) | (10.55M) |
| Effect of Forex Changes | 69K | (130K) | 79K | (48K) | 86K |
| Net Change in Cash | (1.43M) | (8.06M) | (13.46M) | (15.71M) | 322K |
| Free Cash Flow | 3.25M | (3.08M) | (7.22M) | (2.33M) | 4.36M |
Anika Therapeutics, Inc.
NASDAQ:ANIK
Intrinsic Alpha fair value
Locked
Current Price
$13.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.